All Blogs
Dec 12, 2024
Stereotaxis and Shanghai MicroPort EP Medtech Co., Ltd. Receives Approval for Magbot Robotic Magnetic Navigation Ablation Catheter From China’s NMPA; AngioDynamics NanoKnife® System Approved by FDA for Prostate Tissue Treatment; Zynex Successfully Completes Laser Pulse Oximetry Clinical Trial; COTA, PreciseDx, and Baptist Health Validate AI-Powered PreciseBreast as Equivalent to Oncotype DX; Medtronic Introduces Percept™ RC Rechargeable Neurostimulator; Crown Aesthetics Raises the Bar with the Introduction of SkinPen® Precision Elite
China's NMPA Approved Magbot Robotic Magnetic Navigation Ablation Catheter On December 9, 2024, Stereotaxis and Shanghai MicroPort EP Medtech Co., Ltd., announced that the Magbot™ Magnetic Navigation Ablation Catheter received regulatory approval from China’s National Medical Products Administration (NMPA). T...
Read More...
Dec 11, 2024
The Rising Role of Biosensors in Modern Technology
Biosensors are rapidly gaining prominence across various industries, from healthcare and environmental monitoring to food safety and defense. These devices, which combine biological components with sensor technology, offer the potential to detect specific biological substances with high precision and efficiency. As...
Read More...
Dec 10, 2024
AbbVie Reveals Phase III TEMPO-2 Trial Positive Topline Results; FDA Accepts GSK’s NUCALA Submission in COPD; Novartis Boosts Huntington’s Disease Development Program with PTC518 In-Licensing; Chimerix to File for Accelerated FDA Approval of Dordaviprone for H3 K27M-Mutant Diffuse Glioma; MeiraGTx Receives FDA RMAT Designation for AAV2-hAQP1 in Grade 2/3 Radiation-Induced Xerostomia Treatment
AbbVie Unveils Positive Phase III TEMPO-2 Trial Findings for Tavapadon as Parkinson's Disease Monotherapy AbbVie announced favorable topline results from its pivotal Phase III TEMPO-2 trial, which assessed the investigational drug tavapadon as a flexible-dose monotherapy for early-stage Parkinson's disease. Tava...
Read More...
Dec 09, 2024
How CDK4/6 Inhibitors Are Changing the Cancer Treatment Paradigm?
In the rapidly evolving landscape of cancer therapy, one class of drugs is making waves for its game-changing impact: CDK4/6 inhibitors. These revolutionary agents are rewriting the narrative for treating cancers driven by uncontrolled cell division, particularly hormone receptor-positive, HER2-negative breast canc...
Read More...
Dec 06, 2024
Top 6 Celiac Disease Therapies Progressing in Mid-Stage Trials
At present, there are no FDA-approved celiac disease therapies in the therapeutic segment. The only available treatment is a strict, lifelong gluten-free diet, which can be costly and challenging to follow. Many patients experience incomplete intestinal healing and persistent symptoms, often due to difficulties in ...
Read More...
Dec 05, 2024
FDA Approves Zimmer Biomet’s Oxford® Cementless Partial Knee; ReCerf® Sets Milestone as First All-Ceramic Hip Resurfacing Approved Worldwide; Orthocell Achieves US FDA 510(k) Clearance Milestone for Remplir Regulatory Study; Hologic’s Research Shows AI Breast Imaging Maintains Performance Across All Demographics; GE HealthCare Expands MRI Capabilities with Sonic DL’s Advanced Deep Learning; Terumo Unveils the R2P NaviCross Peripheral Support Catheter
Zimmer Biomet Received FDA Approval for Oxford® Cementless Partial Knee, the Only Cementless Partial Knee Replacement Implant in the U.S. On November 25, 2024, Zimmer Biomet Holdings, Inc., a global leader in medical technology, announced that its Oxford® Cementless Partial Knee received Premarket Approval...
Read More...
Dec 04, 2024
Biochips in Healthcare: 8 Groundbreaking Applications Shaping the Industry
Biochips, small devices that integrate biological materials and electronic components, have revolutionized healthcare by enabling rapid, precise, and cost-effective diagnostic and therapeutic solutions. These microdevices combine microfluidics, biosensors, and nanotechnology to analyze and manipulate biological inf...
Read More...
Dec 03, 2024
FDA Grants Fast Track for Lin BioScience’s LBS-007; Alnylam’s AMVUTTRA sNDA Under Review; FDA Approves RAPIBLYK for Atrial Fibrillation; Applied Therapeutics Receives CRL for Govorestat in Galactosemia; R289 Gets Fast Track for Lower-Risk MDS.
Lin BioScience Receives FDA Fast Track Designation for LBS-007 Lin BioScience, a clinical-stage biopharmaceutical company focused on developing innovative therapies for acute leukemia, announced that its lead pipeline candidate, LBS-007, has been granted Fast Track Designation by the FDA for the treatment of acu...
Read More...
Dec 02, 2024
Celiac Disease Treatment: Who Will Secure First-Mover Advantage?
Celiac disease is considered a serious autoimmune disease, which is estimated to affect 1 in 100 people worldwide. Moreover, 2.5 million Americans are undiagnosed and are at risk for long-term health complications. As per secondary, commonly known clinical types of celiac disease include Classical, Non-cla...
Read More...
Nov 29, 2024
From Beta to Alpha Emitters: Radioligand Therapies Reshaping the Neuroendocrine Tumors Treatment Landscape
Radioligand therapies are rapidly transforming the neuroendocrine tumor treatment landscape, offering new hope to patients and reshaping the market dynamics. This innovative approach, which combines the precision of targeted therapy with the potency of radiation, is gaining significant traction in the oncology comm...
Read More...